Diaceutics PLC (DXRX) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, ladies and gentlemen. Welcome to Diacutex half-year results investor presentation. Throughout this recorded meeting, attendees will be in listen-only mode. Questions are encouraged and can be submitted at any time using the Q&A tab situated on the right-hand corner of your screen. Please simply type in your questions at any time and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today, and we'll publish those on the InvestorMeet company platform. Before we begin, we'd like to submit the following poll, and if you could give that your kind attention, I'm sure the company would be most grateful. And I'd like to hand over to CEO Ryan Keeling. Good afternoon. Thank you and good afternoon to all of you joining the call today. We're delighted to host you and hopefully you'll find the session today informative and share some of the excitement we have about the business. as we report our H1 numbers and also look towards full year 2024. And we feel there's a lot to like from H1. I'm going to walk you through our investment case as it exists. But of course, we have updated based on the performance of the business through the first half of the year. And I'll be careful to call out were that evolution of our business model has occurred and how we are gaining traction toward some of our end goals. If I start by reminding us on the problem that we're solving, you know, always a great place to start when you try to understand a business. And for those of you who have followed us, there are many on this call who might be hearing this for the first time. The headline here is that we help pharma find patients. And that is a very true statement. We a...